Skip to content
GLP-1 Desk
Menu

Head-to-head dispatch

Next Vial vs Oak

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Dispatch #285
Next Vial

Fully online GLP-1 telehealth marketplace connecting patients with licensed providers for compounded semaglutide and tirzepatide injections, including microdose options.

$250/mo (compounded) sema · Verified July 3, 2026

Marked down on: Tirzepatide pricing not listed publicly (starting price covers GLP-1 generally)

vs
Dispatch #114Desk pick
Oak

Nationwide, package-based and quick to approve, at $200/mo for compounded semaglutide and $250 for tirzepatide — one flat rate at every dose. The catch is not secrecy but inconsistency: its advertising carries nine different "starting" prices and none of them is what it charges.

$250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning sema · $300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning tirz · Verified August 8, 2026

Marked down on: Oak's MARKETING layer publishes nine different "starting" figures — $119, $133, $160, $167, $180, $185, $190, $199 and $250 — and attaches a term or billing cadence to none of them. None of the nine is what it charges: its own funnel quotes $200/mo semaglutide and $250/mo tirzepatide, one flat rate at every dose

Oak takes this head-to-head with the higher Desk Score, 71/100 (C) against 62/100 (C) for Next Vial. Next Vial still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

Next Vial

62/100

C

Overall

Oak

71/100

C

Price transparency

30
45

State access

78
95

Molecule range

53
62

Onboarding speed

78
92

Support responsiveness

72
72

Licensing & trust

86
70

The spec sheet

FieldNext VialOak
Semaglutide$250/mo (compounded)$250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning
TirzepatideNot listed on Next Vial's site (checked July 3, 2026)$300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning
Coverage49 statesAll 50 states
Brand-nameCompounded onlyCompounded only
Oral optionInjectable onlyInjectable only
Best forPeople seeking compounded GLP-1 care with LegitScript certification and a named pharmacy partner.People who want nationwide package-based care and are willing to complete a long intake before learning what they will actually pay.
Desk Score62/100C71/100C

The verdict

Desk pick — Oak

Oak takes this head-to-head with the higher Desk Score, 71/100 (C) against 62/100 (C) for Next Vial. Next Vial still holds its ground where its strengths line up with yours.

Choose Next Vial if…

People seeking compounded GLP-1 care with LegitScript certification and a named pharmacy partner.

$250/mo (compounded) sema · 49 states

Choose Oak if…

People who want nationwide package-based care and are willing to complete a long intake before learning what they will actually pay.

$250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning sema · $300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning tirz · All 50 states

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Next Vial · Oak.

Also here

CoreAge Rx tops every dispatch at 94/100

Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: one price at every dose, both molecules, all 50 states — but the $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.